This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and evaluation of a novel long-acting interleukin-7 (NT-I7) therapy in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The $639,004 award to Mayo Clinic will fund the collection and analysis of pre- and post-treatment tumor tissue and blood samples to assess the immunotherapeutic effects of NT-I7. Additionally, preclinical studies will be conducted to elucidate the mechanisms by which NT-I7 enhances CD8 T cell trafficking and infiltration into the central nervous system for improved anti-tumor efficacy. This research aims to mitigate treatment-related lymphopenia and enhance response to immunotherapy, ultimately improving survival outcomes for glioblastoma patients.
Generated 3/4/25, 8:42 AM